



**Howard Mayer, M.D.**  
Executive Vice President  
and Head of Research  
and Development

**Dr. Mayer is Executive Vice President and Head of Research and Development at Ipsen. Howard joined Ipsen in 2019 from Shire, where he was Chief Medical Officer, responsible for the hematology, immunology, oncology, genetic diseases, GI/metabolic, neuroscience and ophthalmology therapeutic areas.**

Previously, Howard served as Chief Medical Officer at EMD Serono, a division of Merck KGaA. Prior to that, he held a variety of global roles at Pfizer, including Head, Clinical Development and Medical Affairs for Virology/Infectious Diseases. Prior to joining Pfizer, he served as Director of Clinical Research at Bristol-Myers Squibb.

Howard obtained his BA from the University of Pennsylvania and his M.D. from Albert Einstein College of Medicine, which was followed by an internship and residency at Mount Sinai Hospital and an Infectious Diseases fellowship at Harvard Medical School. He currently serves on the board of directors for Adagio Therapeutics and Entasis Therapeutics, and on the board of Autism Speaks in New England. He was honored by PharmaVoice as one of the 100 Most Inspiring People in the Life Sciences Industry in both 2011 and 2017.

**During the ESMO interviews, Howard will provide a pipeline update highlighting Ipsen's progress across the cancer landscape, and the new combination approaches under investigation in the pursuit of innovative therapies which deliver for people with cancer.**